After spending 20 years at Novartis, Radiopharm Theranostics Ltd. CEO Riccardo Canevari told BioWorld that when he joined Radiopharm he wanted to focus on something different within ...
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumorsSOUTH SAN FRANCISCO, ...
Researchers from the National University of Singapore (NUS) have discovered that cancer cells do not simply push through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results